Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV ...
WEBSep 12, 2024 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the results of an interim analysis from a second pivotal Phase 3 clinical trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
Gilead’s Innovative HIV Treatment Research Pipeline ... - Gilead Sciences
WEBMar 5, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis …
Twice-yearly shot proves successful at preventing HIV infection ... - CNN
WEBJul 24, 2024 · The twice-yearly injection of the drug lenacapavir can provide total protection against HIV infections, demonstrating 100% efficacy in Phase 3 trial data released by drugmaker Gilead and...
Gilead Presents Research Data Across Its Broad and Innovative HIV ...
WEBJul 25, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
WEBJun 20, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new...
Gilead Agrees to Allow Generic Version of ... - The New York Times
WEB22 hours ago · The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North Africa to make and sell at a lower price its groundbreaking drug ...
New HIV drug can only offer hope of ending AIDS if all have …
WEBJul 10, 2024 · New HIV drug can only offer hope of ending AIDS if all have access, UNAIDS says. GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention.
Gilead Signs Royalty-Free Voluntary Licensing Agreements With …
WEB1 day ago · FOSTER CITY, Calif., October 02, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical ...
Gilead Sciences, Inc. - Gilead’s Twice-Yearly Lenacapavir for HIV ...
WEBSep 12, 2024 · Gilead researchers have developed 12 HIV medications , including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.
News Details - Gilead Sciences
WEBJun 20, 2024 · Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.